Cormorant Asset Management added 251,600 shares in Rapport Therapeutics; the reported position value increased by ...
Structure Therapeutics (GPCR) just moved its obesity pipeline up a gear by kicking off a first in human Phase 1 trial for ACCG-2671, its oral amylin receptor agonist targeting metabolic disease. See ...
An announcement from Solvonis Therapeutics ( ($GB:SVNS) ) is now available. Solvonis Therapeutics reported broad progress across its CNS pipeline ...
Fintel reports that on December 22, 2025, Jefferies initiated coverage of Relmada Therapeutics (NasdaqCM:RLMD) with a Buy recommendation. Analyst Price Forecast Suggests 134.48% Upside As of December ...
On December 11, Wedbush analyst Laura Chico maintained her bullish stance on Denali Therapeutics (NASDAQ:DNLI).
On December 18, H.C. Wainwright analyst Joseph Pantginis reaffirmed his Buy rating on Viking Therapeutics (NASDAQ:VKTX).
Ace Therapeutics recently launched in vivo efficacy testing services for IBD drug candidates. Ace Therapeutics, a preclinical ...
CRISPR Therapeutics shares early autoimmune and lymphoma data for zugo-cel, showing strong responses, manageable safety, and ...
Based on the positive global Phase III MANEUVER study, the National Medical Products Administration (NMPA) has granted the ...
Four autoimmune patients treated to date demonstrate deep B-cell depletion sustained for at least 28 days; initial efficacy ...
Director Beth C. Seidenberg of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) recently purchased 133,333 shares of common stock at a price of $7.50 per share, according to a Form 4 filing with the ...
Westlake BioPartners through Westlake BioPartners Opportunity Fund I, L.P. entities, reported purchasing 133,333 shares of Kyverna Therapeutics Inc (NASDAQ:KYTX) common stock at a price of $7.50 on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback